Эрфонрилимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2367013-69-0

immunoglobulin G1 VH-VH-h-CH2-CH3 dimer, anti-[Homo sapiens CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)] and anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], chimeric and humanized monoclonal antibody, bispecific;
gamma1 VH-VH-h-CH2-CH3 chain, chimeric and humanized (1-493) [VH anti-CD274 Vicpac/Homsap (Vicugna pacos IGHV3-3*01 (80.6%) -(IGHD) -IGHJ5*01 (92.3)/Homo sapiens IGHV3-64*04 (78.4%) -(IGHD) -IGHJ1*01 (92.9%)) CDR-IMGT [8.8.21] (26-33.51-58.97-117) (1-128)] -3-mer glycyl-alanyl-prolyl linker (129-131) -[VH anti-CTLA4 humanized (Homo sapiens IGHV3-NL1*01 (86.6%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.8.21] (157-164.182-189.228-248) (132-259)] -2-mer glycyl-seryl linker (260-261) -[Homo sapiens IGHG1*01, G1m1 D12, L14, G1v37 h S5, hinge-CH2-CH3 (100%) (hinge 1-15 C5>S (266) (262-276), CH2 (277-386), CH3 D12 (402), L14 (404) (387-491), CHS (492-493)) (262-493)], dimer (272-272'':275-275'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей